ERBB2 and breast carcinoma: A study showed that premenopausal women with breast cancer, aged ≤ 40 years, had a 40% higher mortality risk than older women6, and women aged ≤ 40 years with HR+/HER2- breast cancer had a two-fold higher mortality risk than older women with the same type of disease6.